Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00101335 · ClinicalTrials.gov registry record · Phase 2
Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00101335: Completed Phase 2 study, sponsored by Fox Chase Cancer Center.
NCT00101335 is a Phase 2 study that has completed, run by Fox Chase Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00101335, a Phase 2 study, has completed, sponsored by Fox Chase Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of celecoxib may prevent or treat head and neck cancer. PURPOSE: This randomized phase II trial is studying celecoxib to see how well it works compared to placebo in preventing head and neck cancer in patients with oral leukoplakia.
Interventions
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-11 |
| Est. Completion | 2005-01 |
| Phase | Phase 2 |
What the finished NCT00101335 record still lists
NCT00101335 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which celecoxib is the first listed.
NCT00101335 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00101335 about?
NCT00101335 is a clinical study titled "Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia". RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of celecoxib may prevent or treat head and neck cancer. PURPOSE: This randomized phase II trial is studying celecoxib to see how well it works compared to placebo in preventing head ...
What is the current status of trial NCT00101335?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-11. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00101335?
The interventions under investigation include: celecoxib (DRUG).
Who is sponsoring clinical trial NCT00101335?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia